News

Enlarge image

BusinessHungaryPoland

Hungary and Poland join forces

24.05.2013 - Hungary and Poland will cooperate to create a biotech cluster with global reach.

On the first day of the Bioforum conference in Budapest, the heads of the Polish and Hungarian biotech associations signed a cooperation agreement aimed at creating a joint cluster. „Hungary and Poland separately are not able to build an effective and strong business cluster for the biotech sector,“ said Erno Duda, President of the Hungarian Biotech Association (HBA). „After having signed this cooperation agreement we have a great chance to create such a cluster, which will develop in scale of international biotech market and, at the same time, will support local initiative and start-ups.“ Tadeusz Pietrucha, who heads the recently launched Polish Biotech Association (PBA) added: „The global biotech market is hard to reach for small and medium companies from the CEE region. Therefore, we have to cooperate to show our potential in…the biotech world”.

The agreement summarises the most pressing needs of the life sciences sector in both nations but also in the whole Central and Eastern Europe (CCE) region. Both associations will join their forces and their member companies’ skills to attract more national funding and EU grants as well as international collaborators from the biotech and pharmaceutical sector. The plan is supported by their national governments, represented by Grazyna Henclewska, undersecretary of Polish Ministry of Economy and by Zoltán Cséfalvay, vice-minister of Hungarian National Economy, at the  conference.

Biotechnology plays an increasing role in the CEE countries. While the sector is young, it is growing and has a strong science base, with biosimilar drug developers, clinical and contract research organisations, and life sciences research companies. Most recently, IBM signed an agreement with Poland’s new Centre for Pre-clinical Research and Technology (CePT), a €100m EU investment aimed at pooling researcher know-how from three universities and seven research institutes to create a fully integrated drug discovery and diagnostics value chain.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-02/hungary-and-poland-join-forces.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK8.85%
  • HYBRIGENICS (F)0.94 EUR8.05%
  • IXICO (UK)31.50 GBP5.00%

FLOP

  • ARGEN-X (B)13.70 EUR-3.52%
  • VECTURA (UK)132.10 GBP-3.17%
  • SAREUM HOLDINGS (UK)0.72 GBP-2.70%

TOP

  • NORDIC NANOVECTOR (N)33.60 NOK37.1%
  • KARO BIO (S)43.00 SEK30.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)6.15 SEK28.1%

FLOP

  • BIONOR PHARMA (N)0.42 NOK-26.3%
  • E-THERAPEUTICS (UK)11.50 GBP-14.1%
  • GW PHARMACEUTICALS (UK)519.00 GBP-12.8%

TOP

  • NICOX (F)10.31 EUR431.4%
  • SAREUM HOLDINGS (UK)0.72 GBP227.3%
  • GENMAB (DK)1095.00 DKK83.3%

FLOP

  • BB BIOTECH (D)44.55 EUR-82.8%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)96.20 GBP-71.9%

No liability assumed, Date: 30.08.2016